CYP2D6 and CYP3A4 in opioid metabolism: Time to develop guidance for PGX biomarkers?

24. september 2017 at 13:32 | Veronika Valdova, ARETE-ZOE |  Medicine & Pharmacy
Clinically relevant insight into genetic makeup and phenotypic biomarkers, such as ADMET and treatment outcomes, would significantly improve predictability of individual response to medications. The combination of metabolomic and pharmacogenomic data from individual patients would offer better insight compared to genotyping alone, especially in patients who take multiple interacting drugs at a time.

Opioid overdose
Adverse drug events (ADEs) account for an estimated one-third of hospital adverse events and approximately 280,000 hospital admissions annually. Three types of ADEs were selected as high-priority targets as common, clinically significant, preventable, and measurable: Anticoagulants (primary concern: bleeding), diabetes agents(hypoglycemia) and opioids (accidental overdoses/oversedation /respiratory depression) (National Action Plan for ADE prevention, 2014)

Anticoagulants, antidiabetic agents, and opioid analgesics are responsible for ~60% of ED visits for adverse drug events among older adults (ADE Change Package, 2017)


New comment

Log in
  Don't you have your own web yet? Create it for free on

Actual articles